ArticleCancer medicine2024

Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.

Courtney D DiNardo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.